Evidence map›Paper›PMID 40921899›Full record

ArticleAnnals of surgical oncology2025

Advancing Prognostics in Oncology: Developing a Machine Learning Model for Predicting 2-Year and 5-Year Survival Rates in Patients with Undifferentiated Pleomorphic Sarcoma.

Andrew G Girgis, Bishoy M Galoaa, Marcos R Gonzalez, Santiago A Lozano-Calderon

Abstract read
PubMed Publisher
In one paragraph

Article in Annals of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Andrew G Girgis *Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA.
Bishoy M Galoaa *Orthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA.
Marcos R GonzalezOrthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA.
Santiago A Lozano-CalderonOrthopaedic Oncology Service, Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, MA, USA. slozanocalderon@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-0681-9004

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUndifferentiated pleomorphic sarcoma (UPS) is a prevalent soft tissue sarcoma subtype associated with poor prognosis. Current prognostic tools lack the ability to incorporate personalized data for predicting survival. Machine learning (ML) offers a potential solution to enhance survival prediction accuracy. This study aimed to develop and validate a new ML algorithm to predict 2- and 5-year overall survival (OS) in patients with UPS. PATIENTS AND

methodsWe included 3494 patients with a histologic diagnosis of UPS from the Surveillance, Epidemiology, and End Results (SEER) database for model training and internal validation. An institutional database of 288 patients was used for external validation. The development of the ML model involved converting tabular patient data into high-dimensional embeddings using a pre-trained language model. A custom neural network, optimized for high-dimensional data, was then developed to classify survival outcomes. Area under the curve (AUC), precision, and F1-scores were used to assess model performance.

resultsTumor size, age, metastases, lymph node involvement, and sex were factors associated with OS. On internal validation, our model showed higher performance than standard ML models for both 2-year and 5-year OS (AUC of 0.81 and 0.82, respectively). On external validation, the model showed excellent discriminative performance for the 2-year (AUC = 0.79) and 5-year OS (AUC = 0.81). In addition, we showed that our developed model performed superiorly compared with other models.

conclusionsWe successfully developed and validated an ML algorithm that accurately predicts 2-year and 5-year OS in patients with UPS. To confirm generalizability, further external validation of this algorithm is encouraged.

Indexed as

Machine learningPrognosis predictionSoft tissue sarcomaSurvival

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.